Avalo Therapeutics Cash Flow Statement
NASDAQ: AVTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
13.65+0.22 (+1.64%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Avalo Therapeutics free cash flow
In fiscal 2025, Avalo Therapeutics generated -$51.5 million of operating cash flow. That left free cash flow of -$51.5 million, a free-cash-flow margin of -87216.9% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Avalo Therapeutics cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -78.26M | -35.13M | -31.54M | -41.66M | -84.38M | -63.50M | -16.07M | -40.05M | 11.87M | -16.47M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | -437.43% | — | — |
| Depreciation & Amortization | 344.00K | 169.00K | 158.00K | 166.00K | 1.66M | 1.84M | 3.88M | 4.55M | 425.48K | 26.86K |
| Stock-Based Compensation | 13.62M | 5.85M | 3.48M | 7.55M | 8.17M | 6.79M | 2.53M | 2.43M | 1.16M | 1.69M |
| Change in Working Capital | -2.73M | -3.03M | -2.06M | 1.76M | 2.17M | -2.42M | 2.29M | -692.92K | -353.10K | 221.68K |
| Operating Cash Flow | -51.46M | -49.06M | -30.68M | -26.75M | -70.89M | -40.54M | -19.13M | -3.13M | 12.58M | -14.57M |
| Capital Expenditures | — | 0 | -158.00K | -95.00K | -113.00K | -63.00K | -262.01K | -564.41K | -23.32K | -34.88K |
| Investing Cash Flow | -81.72M | 356.00K | -133.00K | -95.00K | -113.00K | 11.13M | -443.00K | 865.46K | -18.91M | -34.88K |
| Debt Repaid | — | 0 | -21.24M | 0 | 0 | 0 | -256.14K | 0 | -2.37M | -3.31M |
| Financing Cash Flow | 14.59M | 175.85M | 25.04M | -14.70M | 106.76M | 44.78M | 12.56M | 10.40M | 3.74M | -1.43M |
| Net Change in Cash | -118.59M | 127.15M | -5.77M | -41.55M | 35.76M | 15.38M | -7.02M | 8.14M | -2.60M | -16.03M |
| Free Cash Flow | -51.46M | -49.06M | -30.84M | -26.85M | -71.00M | -40.60M | -19.40M | -3.69M | 12.56M | -14.61M |
This table shows 10 annual periods of Avalo Therapeutics's cash flow statement, from FY 2025 back to FY 2016, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow AVTX's reporting calendar. What is a cash flow statement?